Lasinavir

Drug Profile

Lasinavir

Alternative Names: BMS 234475; CGP 61755

Latest Information Update: 09 Oct 2002

Price : $50

At a glance

  • Originator Novartis
  • Developer Bristol-Myers Squibb
  • Class Antivirals
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 09 Oct 2002 Discontinued - Phase-I for HIV infections treatment in USA (PO)
  • 12 Feb 1999 BMS 234475 is now called lasinavir
  • 17 Jul 1997 Phase-I clinical trials for HIV infections treatment in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top